May 23, 2016Journal of the American College of Cardiology
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
No abstract yet
We only have this paper's title and publication details.
Read it at the sourceKey expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Not every patient is a good candidate for every drug; these guidelines can help physicians decide who best fits which treatment. This document details the benefits and risks of these new therapies so that patients at high risk can be directed toward alternative therapies.”
EMElliott M. AntmanCardiologist, Brigham and Women's Hospital
“The introduction of an angiotensin receptor-neprilysin inhibitor (ARNI), valsartan/sacubitril, and a sinoatrial node modulator, ivabradine, when applied judiciously, complement established pharmacological and device-based therapies, representing milestones in the evolution of care for patients with heart failure.”
“Treatment options for patients with heart failure have expanded considerably. There is more hope than ever before for patients with heart failure. These guideline recommendations will serve as a tool to guide the choice of therapy and in turn improve outcomes.”
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Yancy et al. (2016) studied this question.